{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:23:16Z","timestamp":1790677396373,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adult onset Pompe disease is a genetic disorder characterized by slowly progressive skeletal and respiratory muscle weakness. Symptomatic patients are treated with enzymatic replacement therapy with human recombinant alfa glucosidase. Motor functional tests and spirometry are commonly used to follow patients up. However, a serological biomarker that correlates with the progression of the disease could improve follow-up. We studied serum concentrations of TGF\u03b2, PDGF-BB, PDGF-AA and CTGF growth factors in 37 adult onset Pompe patients and 45 controls. Moreover, all patients performed several muscle function tests, conventional spirometry, and quantitative muscle MRI using 3-point Dixon. We observed a statistically significant change in the serum concentration of each growth factor in patients compared to controls. However, only PDGF-BB levels were able to differentiate between asymptomatic and symptomatic patients, suggesting its potential role in the follow-up of asymptomatic patients. Moreover, our results point to a dysregulation of muscle regeneration as an additional pathomechanism of Pompe disease.<\/jats:p>","DOI":"10.1038\/s41598-018-38025-0","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T11:03:38Z","timestamp":1550142218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["PDGF-BB serum levels are decreased in adult onset Pompe patients"],"prefix":"10.1038","volume":"9","author":[{"given":"Esther","family":"Fern\u00e1ndez-Sim\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Carrasco-Rozas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3942-3436","authenticated-orcid":false,"given":"Eduard","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Figueroa-Bonaparte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izaskun","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Montiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Su\u00e1rez-Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Alonso-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Segovia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Nu\u00f1ez-Peralta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Llauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Mayos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Illa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Spanish Pompe Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Barba-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseba","family":"Barcena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Rosario","family":"Carzorla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Creus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Coll-Cant\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"de Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Fern\u00e1ndez-Torr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Garc\u00eda-Antelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Mar\u00eda","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"G\u00f3mez-Caravaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Le\u00f3n-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"L\u00f3pez\u00a0de Mun\u00e1in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Antonio","family":"Mart\u00ednez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Morgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"Mor\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Mu\u00f1oz-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Paradas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Paraju\u00e1-Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Robledo-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Rojas-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cd\u00f1igo","family":"Rojas-Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Us\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"D\u00edaz-Manera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"38025_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg, A. T. & Reuser, A. J. J. Pompe\u2019s disease. Lancet (London, England) 372, 1342\u201353 (2008).","journal-title":"Lancet (London, England)"},{"key":"38025_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11910-007-0024-4","volume":"7","author":"T Fukuda","year":"2007","unstructured":"Fukuda, T., Roberts, A., Plotz, P. H. & Raben, N. Acid alpha-glucosidase deficiency (Pompe disease). Curr. Neurol. Neurosci. Rep. 7, 71\u20137 (2007).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"38025_CR3","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1212\/WNL.0b013e31818da91e","volume":"71","author":"B Bembi","year":"2008","unstructured":"Bembi, B. et al. Diagnosis of glycogenosis type II. Neurology 71, S4\u201311 (2008).","journal-title":"Neurology"},{"key":"38025_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jpeds.2015.10.078","volume":"169","author":"C-F Yang","year":"2016","unstructured":"Yang, C.-F. et al. Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes. J. Pediatr. 169, 174\u2013180.e1 (2016).","journal-title":"J. Pediatr."},{"key":"38025_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0771-0","volume":"13","author":"R Parini","year":"2018","unstructured":"Parini, R. et al. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy. Orphanet J. Rare Dis. 13, 32 (2018).","journal-title":"Orphanet J. Rare Dis."},{"key":"38025_CR6","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","volume":"64","author":"MLC Hagemans","year":"2005","unstructured":"Hagemans, M. L. C. et al. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 64, 2139\u20132141 (2005).","journal-title":"Neurology"},{"key":"38025_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ajmg.c.31322","volume":"160C","author":"A Sch\u00fcller","year":"2012","unstructured":"Sch\u00fcller, A., Wenninger, S., Strigl-Pill, N. & Schoser, B. Toward deconstructing the phenotype of late-onset Pompe disease. Am. J. Med. Genet. Part C Semin. Med. Genet. 160C, 80\u201388 (2012).","journal-title":"Am. J. Med. Genet. Part C Semin. Med. Genet."},{"key":"38025_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ymgme.2015.09.001","volume":"116","author":"PT McIntosh","year":"2015","unstructured":"McIntosh, P. T., Case, L. E., Chan, J. M., Austin, S. L. & Kishnani, P. Characterization of gait in late onset Pompe disease. Mol. Genet. Metab. 116, 152\u20136 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"38025_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/srep37040","volume":"6","author":"MS Valle","year":"2016","unstructured":"Valle, M. S. et al. Quantitative analysis of upright standing in adults with late-onset Pompe disease. Sci. Rep. 6, 37040 (2016).","journal-title":"Sci. Rep."},{"key":"38025_CR10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg, A. T. et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur. J. Neurol. 24, 768\u2013e31 (2017).","journal-title":"Eur. J. Neurol."},{"key":"38025_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0412-3","volume":"15","author":"MENAP Working Group","year":"2015","unstructured":"Working Group, M. E. N. A. P. F. et al. Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group. BMC Neurol. 15, 205 (2015).","journal-title":"BMC Neurol."},{"key":"38025_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev.physiol.010908.163216","volume":"71","author":"GQ Wallace","year":"2009","unstructured":"Wallace, G. Q. & McNally, E. M. Mechanisms of Muscle Degeneration, Regeneration, and Repair in the Muscular Dystrophies. Annu. Rev. Physiol. 71, 37\u201357 (2009).","journal-title":"Annu. Rev. Physiol."},{"key":"38025_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1474-4422(15)00242-2","volume":"15","author":"JM Morrow","year":"2016","unstructured":"Morrow, J. M. et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol. 15, 65\u201377 (2016).","journal-title":"Lancet Neurol."},{"key":"38025_CR14","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1474-4422(16)30035-7","volume":"15","author":"V Straub","year":"2016","unstructured":"Straub, V. et al. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet. Neurol. 15, 882\u2013890 (2016).","journal-title":"Lancet. Neurol."},{"key":"38025_CR15","doi-asserted-by":"publisher","first-page":"e0163493","DOI":"10.1371\/journal.pone.0163493","volume":"11","author":"S Figueroa-Bonaparte","year":"2016","unstructured":"Figueroa-Bonaparte, S. et al. Muscle MRI Findings in Childhood\/Adult Onset Pompe Disease Correlate with Muscle Function. PLoS One 11, e0163493 (2016).","journal-title":"PLoS One"},{"key":"38025_CR16","doi-asserted-by":"publisher","first-page":"10898","DOI":"10.1038\/s41598-018-29170-7","volume":"8","author":"S Figueroa-Bonaparte","year":"2018","unstructured":"Figueroa-Bonaparte, S. et al. Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study. Sci. reports 8, 10898 (2018).","journal-title":"Sci. reports"},{"key":"38025_CR17","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.matbio.2018.01.014","volume":"68\u201369","author":"LR Smith","year":"2018","unstructured":"Smith, L. R. & Barton, E. R. Regulation of fibrosis in muscular dystrophy. Matrix Biol. 68\u201369, 602\u2013615 (2018).","journal-title":"Matrix Biol."},{"key":"38025_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/ncb2015","volume":"12","author":"AWB Joe","year":"2010","unstructured":"Joe, A. W. B. et al. Muscle injury activates resident fibro\/adipogenic progenitors that facilitate myogenesis. Nat. Cell Biol. 12, 153\u2013163 (2010).","journal-title":"Nat. Cell Biol."},{"key":"38025_CR19","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1083\/jcb.111.4.1623","volume":"111","author":"Z Yablonka-Reuveni","year":"1990","unstructured":"Yablonka-Reuveni, Z., Balestreri, T. M. & Bowen-Pope, D. F. Regulation of proliferation and differentiation of myoblasts derived from adult mouse skeletal muscle by specific isoforms of PDGF. J. Cell Biol. 111, 1623\u20139 (1990).","journal-title":"J. Cell Biol."},{"key":"38025_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0002-9440(10)63188-4","volume":"164","author":"Y Li","year":"2004","unstructured":"Li, Y. et al. Transforming Growth Factor-\u03b21 Induces the Differentiation of Myogenic Cells into Fibrotic Cells in Injured Skeletal Muscle. Am. J. Pathol. 164, 1007\u20131019 (2004).","journal-title":"Am. J. Pathol."},{"key":"38025_CR21","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/cbin.10725","volume":"41","author":"D Kamila","year":"2017","unstructured":"Kamila, D., Paulina, K., A, C. M. & Malgorzata, Z. The role of TGF- \u03b21 during skeletal muscle regeneration \u2020. Cell Biol Int 41, 706\u2013715 (2017).","journal-title":"Cell Biol Int"},{"key":"38025_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00441-009-0889-4","volume":"339","author":"S Zanotti","year":"2010","unstructured":"Zanotti, S., Gibertini, S. & Mora, M. Altered production of extra-cellular matrix components by muscle-derived Duchenne muscular dystrophy fibroblasts before and after TGF-\u03b21 treatment. Cell Tissue Res 339, 397\u2013410 (2010).","journal-title":"Cell Tissue Res"},{"key":"38025_CR23","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/path.4801","volume":"240","author":"N Ieronimakis","year":"2016","unstructured":"Ieronimakis, N. et al. PDGFR signalling promotes fibrogenic responses in collagen-producing cells in Duchenne muscular dystrophy. J. Pathol. J Pathol 240, 410\u2013424 (2016).","journal-title":"J. Pathol. J Pathol"},{"key":"38025_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/2044-5040-1-19","volume":"1","author":"TN Burks","year":"2011","unstructured":"Burks, T. N. & Cohn, R. D. Role of TGF-\u03b2 signaling in inherited and acquired myopathies. Skelet. Muscle 1, 19 (2011).","journal-title":"Skelet. Muscle"},{"key":"38025_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.devcel.2008.12.003","volume":"16","author":"LE Olson","year":"2009","unstructured":"Olson, L. E. & Soriano, P. Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis. Dev. Cell 16, 303\u201313 (2009).","journal-title":"Dev. Cell"},{"key":"38025_CR26","first-page":"1","volume":"27","author":"RT Kendall","year":"2014","unstructured":"Kendall, R. T. & Feghali-Bostwick, C. A. Fibroblasts in fibrosis: Novel roles and mediators. Front. Pharmacol. 27, 1\u201313 (2014).","journal-title":"Front. Pharmacol."},{"key":"38025_CR27","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1517\/14728222.2013.812074","volume":"17","author":"A Leask","year":"2013","unstructured":"Leask, A. CCN2: a novel, specific and valid target for anti-fibrotic drug intervention. Expert Opin. Ther. Targets 17, 1067\u20131071 (2013).","journal-title":"Expert Opin. Ther. Targets"},{"key":"38025_CR28","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/path.2952","volume":"225","author":"MG Morales","year":"2011","unstructured":"Morales, M. G. et al. CTGF\/CCN-2 over-expression can directly induce features of skeletal muscle dystrophy. J. Pathol. 225, 490\u2013501 (2011).","journal-title":"J. Pathol."},{"key":"38025_CR29","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.nmd.2011.06.748","volume":"21","author":"R-Y Carlier","year":"2011","unstructured":"Carlier, R.-Y. et al. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: Involvement patterns. Neuromuscul. Disord. 21, 791\u2013799 (2011).","journal-title":"Neuromuscul. Disord."},{"key":"38025_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10545-015-9825-9","volume":"38","author":"PG Carlier","year":"2015","unstructured":"Carlier, P. G. et al. Skeletal muscle quantitative nuclear magnetic resonance imaging follow-up of adult Pompe patients. J. Inherit. Metab. Dis. 38, 565\u2013572 (2015).","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl 2","key":"38025_CR31","doi-asserted-by":"publisher","first-page":"S148","DOI":"10.1016\/j.nmd.2012.05.011","volume":"22","author":"A Alejaldre","year":"2012","unstructured":"Alejaldre, A. et al. Trunk muscle involvement in late-onset Pompe disease: study of thirty patients. Neuromuscul. Disord. 22(Suppl 2), S148\u201354 (2012).","journal-title":"Neuromuscul. Disord."},{"key":"38025_CR32","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.ajpath.2017.04.011","volume":"187","author":"P Pi\u00f1ol-Jurado","year":"2017","unstructured":"Pi\u00f1ol-Jurado, P. et al. Platelet-Derived Growth Factor BB Influences Muscle Regeneration in Duchenne Muscle Dystrophy. Am. J. Pathol. 187, 1814\u20131827 (2017).","journal-title":"Am. J. Pathol."},{"key":"38025_CR33","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/labinvest.3700484","volume":"86","author":"BL Thurberg","year":"2006","unstructured":"Thurberg, B. L. et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab. Investig. 86, 1208\u20131220 (2006).","journal-title":"Lab. Investig."},{"key":"38025_CR34","doi-asserted-by":"publisher","unstructured":"Schaaf, G. J. et al. Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease, https:\/\/doi.org\/10.1186\/s40478-015-0243-x.","DOI":"10.1186\/s40478-015-0243-x"},{"key":"38025_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40478-018-0609-y","volume":"6","author":"L Lagalice","year":"2018","unstructured":"Lagalice, L. et al. Satellite cells fail to contribute to muscle repair but are functional in Pompe disease (glycogenosis type II). Acta Neuropathol Commun. 6, 116 (2018).","journal-title":"Acta Neuropathol Commun."},{"key":"38025_CR36","doi-asserted-by":"publisher","first-page":"e71900","DOI":"10.1371\/journal.pone.0071900","volume":"8","author":"Y-H Chien","year":"2013","unstructured":"Chien, Y.-H., Han, D.-S., Hwu, W.-L., Thurberg, B. L. & Yang, W.-S. Myostatin and Insulin-Like Growth Factor I: Potential Therapeutic Biomarkers for Pompe Disease. PLoS One 8, e71900 (2013).","journal-title":"PLoS One"},{"key":"38025_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ymgme.2012.05.004","volume":"106","author":"AT Palermo","year":"2012","unstructured":"Palermo, A. T. et al. Transcriptional response to GAA deficiency (Pompe disease) in infantile-onset patients. Mol. Genet. Metab. 106, 287\u2013300 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"38025_CR38","doi-asserted-by":"publisher","unstructured":"Pascarella, A. et al. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy. J. Cell. Physiol. https:\/\/doi.org\/10.1002\/jcp.26365, (2017).","DOI":"10.1002\/jcp.26365"},{"key":"38025_CR39","first-page":"45","volume":"26","author":"N Raben","year":"2007","unstructured":"Raben, N. & Plotz, P. Role of autophagy in the pathogenesis of Pompe disease. Acta Myol. 26, 45\u201348 (2007).","journal-title":"Acta Myol."},{"key":"38025_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/ajmg.c.31320","volume":"160 C","author":"SP Young","year":"2012","unstructured":"Young, S. P. et al. Assessing disease severity in Pompe disease: The roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. Am. J. Med. Genet. Part C Semin. Med. Genet. 160C, 50\u201358 (2012).","journal-title":"Am. J. Med. Genet. Part C Semin. Med. Genet."},{"key":"38025_CR41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10545-011-9360-2","volume":"35","author":"V Manwaring","year":"2012","unstructured":"Manwaring, V. et al. Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases. J. Inherit. Metab. Dis. 35, 311\u2013316 (2012).","journal-title":"J. Inherit. Metab. Dis."},{"key":"38025_CR42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ymgme.2005.03.010","volume":"85","author":"Y An","year":"2005","unstructured":"An, Y. et al. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol. Genet. Metab. 85, 247\u2013254 (2005).","journal-title":"Mol. Genet. Metab."},{"key":"38025_CR43","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/GIM.0b013e3181a87867","volume":"11","author":"SP Young","year":"2009","unstructured":"Young, S. P. et al. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet. Med. 11, 536\u2013541 (2009).","journal-title":"Genet. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38025-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38025-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38025-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T05:57:43Z","timestamp":1671256663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38025-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["38025"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-38025-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,14]]},"assertion":[{"value":"24 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2139"}}